JP2009506054A5 - - Google Patents

Download PDF

Info

Publication number
JP2009506054A5
JP2009506054A5 JP2008528124A JP2008528124A JP2009506054A5 JP 2009506054 A5 JP2009506054 A5 JP 2009506054A5 JP 2008528124 A JP2008528124 A JP 2008528124A JP 2008528124 A JP2008528124 A JP 2008528124A JP 2009506054 A5 JP2009506054 A5 JP 2009506054A5
Authority
JP
Japan
Prior art keywords
composition
hedgehog
cancer
pathway activity
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008528124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506054A (ja
JP5435946B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/032952 external-priority patent/WO2007024971A2/en
Publication of JP2009506054A publication Critical patent/JP2009506054A/ja
Publication of JP2009506054A5 publication Critical patent/JP2009506054A5/ja
Application granted granted Critical
Publication of JP5435946B2 publication Critical patent/JP5435946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008528124A 2005-08-22 2006-08-22 疾患を処置するためのヘッジホッグ経路アンタゴニスト Active JP5435946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71011705P 2005-08-22 2005-08-22
US60/710,117 2005-08-22
PCT/US2006/032952 WO2007024971A2 (en) 2005-08-22 2006-08-22 Hedgehog pathway antagonists to treat disease

Publications (3)

Publication Number Publication Date
JP2009506054A JP2009506054A (ja) 2009-02-12
JP2009506054A5 true JP2009506054A5 (enExample) 2010-08-26
JP5435946B2 JP5435946B2 (ja) 2014-03-05

Family

ID=37772335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008528124A Active JP5435946B2 (ja) 2005-08-22 2006-08-22 疾患を処置するためのヘッジホッグ経路アンタゴニスト

Country Status (7)

Country Link
US (1) US8653083B2 (enExample)
EP (2) EP1919480B1 (enExample)
JP (1) JP5435946B2 (enExample)
AU (1) AU2006283040B2 (enExample)
CA (1) CA2619889C (enExample)
ES (1) ES2403006T3 (enExample)
WO (1) WO2007024971A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20110191868A1 (en) * 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
AU2012304407A1 (en) 2011-09-09 2014-04-24 Children's Hospital & Research Center Oakland Topical itraconazole formulations and uses thereof
US20130225529A1 (en) * 2012-02-27 2013-08-29 Basil Rigas Phospho-ester derivatives and uses thereof
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
ITRM20130366A1 (it) * 2013-06-25 2014-12-26 Univ Roma La Sapienza Multitarget hedgehog pathway inhibitors and uses thereof
WO2015116947A1 (en) * 2014-02-01 2015-08-06 University Of Connecticut Itraconazole analogues and methods of use thereof
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US10512641B2 (en) * 2015-06-01 2019-12-24 University Of Kentucky Research Foundation Chloroquine induction par-4 and treatment of cancer
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
US20180193335A1 (en) * 2015-10-12 2018-07-12 Vikash J. BHAGWANDIN Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
WO2018191541A1 (en) * 2017-04-12 2018-10-18 Bhagwandin Vikash J Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
EP3624798A1 (en) * 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of mast cell diseases
WO2019040363A1 (en) 2017-08-20 2019-02-28 University Of Connecticut Azole analogues and methods of use thereof
CN110279696A (zh) * 2019-07-31 2019-09-27 中国医学科学院皮肤病医院 伊曲康唑在制备抑制肿瘤转移药物中的应用
WO2021030174A1 (en) 2019-08-09 2021-02-18 University Of Connecticut Truncated itraconazole analogues and methods of use thereof
CN113521071A (zh) * 2021-07-22 2021-10-22 广州医科大学 氯喹那多的新应用
CN114081883B (zh) * 2021-11-04 2023-02-28 武汉科技大学 氯喹那多在制备抗肿瘤药物中的应用
JP2025527578A (ja) 2022-08-18 2025-08-22 パルマトリックス オペレーティング カンパニー，インコーポレイテッド 吸入用血管新生阻害剤を用いてがんを治療する方法
WO2024249959A1 (en) * 2023-06-02 2024-12-05 University Of Massachusetts Medical School Compositions reducing the expression or activity of c1 galt1 for treating ewing sarcoma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4824829A (en) 1984-08-15 1989-04-25 American Cyanamid Company Non-dusting antibiotic, anticoccidial premix compositions and a process for their manufacture
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
DK0631578T3 (da) 1992-03-18 2001-08-27 Janssen Pharmaceutica Nv Itraconazol- og saperconazol-stereoisomerer
JPH0782163A (ja) * 1993-09-10 1995-03-28 Pola Chem Ind Inc 肝障害治療剤及びこれを含有する組成物
JPH0782162A (ja) * 1993-09-10 1995-03-28 Pola Chem Ind Inc 皮膚外用剤
WO1995018856A1 (en) 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
AUPN033894A0 (en) 1994-12-29 1995-01-27 Rowe, J.B. Prevention of adverse behaviour in humans and animals
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
PT1039909E (pt) 1997-12-31 2003-02-28 Choongwae Pharma Corp Metodo de producao e composicao de uma preparacao oral de itraconazole
US6277566B1 (en) 1998-02-13 2001-08-21 Phillip A. Beachy Method for identifying a hedgehog-mediated phosphorylation state dependent transcription factor
EP1067939B1 (en) * 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
US6867216B1 (en) 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
ES2157731B1 (es) 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
US6552026B2 (en) 1999-06-14 2003-04-22 Basf Aktiengesellschaft 6-phenyl-pyrazolopyrimidines
US6552016B1 (en) * 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE19963052A1 (de) * 1999-12-24 2001-06-28 Bayer Ag Verwendung von Azolen zur Prävention von Hautkrebs
JP5196700B2 (ja) * 2000-10-13 2013-05-15 キュリス，インコーポレイテッド ヘッジホッグアンタゴニスト、それらに関する方法及び利用
AU2002217911A1 (en) 2000-11-28 2002-06-11 Curis, Inc. Basal cell carcinoma cultures, methods related thereto and their use
AU2001272892B8 (en) * 2001-07-02 2006-05-04 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
US6946137B2 (en) 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20070179152A1 (en) 2003-05-23 2007-08-02 Lee Margaret S Combination therapy for the treatment of neoplasms
WO2005000208A2 (en) 2003-05-30 2005-01-06 Combinatorx, Inc. Combination therapy for the treatment of neoplasms
US20050049207A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
EP1765336A4 (en) 2004-06-25 2010-03-10 Univ Johns Hopkins ANGIOGENESIS INHIBITORS

Similar Documents

Publication Publication Date Title
JP2009506054A5 (enExample)
JP6147799B2 (ja) Ｐａｒｐインヒビターとの組合せ療法
JP2009539769A5 (enExample)
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2005527599A5 (enExample)
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
JP2006503919A5 (enExample)
RU2015155283A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
JP2009515901A5 (enExample)
JP2020523354A5 (enExample)
JP2016522202A5 (enExample)
US20150005354A1 (en) Combination Therapy With Parp Inhibitors
JP2017507151A5 (enExample)
JP2021105005A5 (enExample)
JP2011500805A5 (enExample)
JP2014504636A5 (enExample)
WO2016014390A1 (en) Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
JP2016530208A5 (enExample)
JP2015510945A5 (enExample)
JP5976923B2 (ja) イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP2011500650A5 (enExample)
AR063459A1 (es) Metodo para administrar un inhibidor de aurora en el tratamiento del cancer
US20080280867A1 (en) Combination therapy with parp inhibitors
JP2010519274A5 (enExample)